Cboe Global Markets (CBOE)
BATSFinancialsFinancial - Data & Stock ExchangesSnapshot 2026-09-04
BATSFinancialsFinancial - Data & Stock ExchangesSnapshot 2026-09-04
Research Workspace
Put CBOE beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Financials is in steady. Describes the industry's cycle state, not a call on this stock.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Recent financial performance slipped notably this past month, though still top-half.
View ThesisRevenue growth is slowing — up about 12% over the past year and decelerating.
View GrowthMiddle-of-the-pack quality for its industry.
View QualityMiddle-of-the-pack management execution.
View ManagementExpectations look high — what the market is pricing in runs ahead of what analysts forecast.
View ValuationThis stock is volatile — it swings about 2% on a typical day and fell roughly 37% in its worst 12-month stretch.
View RiskCBOE's growth depends on maintaining its competitive edge in derivatives trading. Recent revenue growth was 25% year over year, and the last quarter beat expectations. It trades at 23× P/E, above the 12× peer median. The market is pricing in more growth than we forecast. A key risk is if CBOE cuts guidance after a recent raise. Peer multiples imply a price about 26% below where it trades. This read is provisional.
Trailing returns as of 2026-09-04. CBOE is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 17 analysts currently covering CBOE (as of Sep 2026).
Based on 4 Wall Street analysts offering 12-month price targets for CBOE in the last 4 months.
Continue this research
Compare CBOE with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Free account required to save the handoff. No credit card.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| CBOE Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 9 valuation methods, at three horizons. As of 2026-09-04. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Financial Exchanges & Data — fair value, gap to price, and forward P/E.
Compare the value case
Put CBOE next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Advances: Maintain disciplined capital allocation including share repurchases and dividen…
Dividend increase supports disciplined capital allocation strategy.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-09-04. EPS is implied from price ÷ P/E. Not investment advice.
Current $298.38
The last 12 months of price, then the range of analyst 12-month targets from today’s $298.38.
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Top 25% on quality vs scored peers
A second lens on the 12-month fair value: for companies that score high on measured quality (profitability, balance-sheet safety, earnings stability), this read trusts more of today's profit margins instead of averaging them toward their multi-year history the way the headline number does. Shown alongside the fair value above, not in place of it. A diagnostic, not a price target or a buy/sell signal.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.

Threatens: Strategic realignment for core business focus
Repositioning may divert focus from core business strategy.
Advances: Strategic realignment for core business focus
Expanding options hours aligns with strategic realignment goals.
Advances: Strategic realignment for core business focus
New trading options align with strategic realignment goals.
Advances: Strategic realignment for core business focus
Launch aligns with strategic realignment for core business focus.
Threatens: Strategic realignment for core business focus
New ETF rivals threaten Cboe's core business focus.